Enzo Biochem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2022
October 14, 2022 at 07:30 am EDT
Share
Enzo Biochem, Inc. reported earnings results for the fourth quarter and full year ended July 31, 2022. For the fourth quarter, the company reported sales was USD 20.28 million compared to USD 24.81 million a year ago. Net loss was USD 8.43 million compared to net income of USD 3.27 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to basic earnings per share from continuing operations of USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.17 compared to diluted earnings per share from continuing operations of USD 0.07 a year ago.
For the full year, sales was USD 107.07 million compared to USD 117.73 million a year ago. Net loss was USD 18.26 million compared to net income of USD 7.88 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to basic earnings per share from continuing operations of USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.38 compared to diluted earnings per share from continuing operations of USD 0.16 a year ago.
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
ENZO BIOCHEM, INC. 
